Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 886 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 How Writing Helped Me Cope During Cancer April 27, 2021 Load more HOT NEWS Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in... Talking About Sexual Health Concerns With Your Cancer Care Team: How... New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients Why investing in cancer research is good for the economy
